Does TRASTUZUMAB DERUXTECAN Cause Tumour marker increased? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Tumour marker increased have been filed in association with TRASTUZUMAB DERUXTECAN (Enhertu). This represents 0.2% of all adverse event reports for TRASTUZUMAB DERUXTECAN.
5
Reports of Tumour marker increased with TRASTUZUMAB DERUXTECAN
0.2%
of all TRASTUZUMAB DERUXTECAN reports
0
Deaths
0
Hospitalizations
How Dangerous Is Tumour marker increased From TRASTUZUMAB DERUXTECAN?
Of the 5 reports.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TRASTUZUMAB DERUXTECAN. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TRASTUZUMAB DERUXTECAN Cause?
Death (384)
Off label use (258)
Nausea (251)
Myelosuppression (242)
Fatigue (186)
Malignant neoplasm progression (171)
Vomiting (140)
Diarrhoea (132)
Interstitial lung disease (130)
Pneumonitis (125)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which TRASTUZUMAB DERUXTECAN Alternatives Have Lower Tumour marker increased Risk?
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DKST
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DTTB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB EMTANSINE
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-PKRB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-QYYP